Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyproheptadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.79 |
| ▸ | SETD7 | Q8WTS6 | 7/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.79 |
| ▸ | DRD1 | P21728 | 4/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.79 |
| ▸ | DRD3 | P35462 | 4/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.79 |
| ▸ | HTR1A | P08908 | 3/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.79 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.79 |
| ▸ | HTR2A | P28223 | 3/20 | 0.79 |
| ▸ | HTR2C | P28335 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyproheptadine SCHEMBL9934753 | 0.89 | LMNA (0.97) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL27756503 | 0.89 | LMNA (0.97) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL29369949 | 0.89 | SETD7 (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL4021 | 0.89 | SETD7 (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL7923153 | 0.89 | SETD7 (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL28514693 | 0.88 | SETD7 (0.90) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL5500354 | 0.88 | LMNA (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL41842 | 0.88 | LMNA (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL20610743 | 0.88 | LMNA (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 | |
| Cyproheptadine SCHEMBL29380652 | 0.88 | LMNA (1.00) | SETD7CHRM2ADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646025-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| EP-2600863-A2 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-06-12 | — | — | EP | disclosed |
| EP-2571501-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-03-27 | — | — | EP | disclosed |
| EP-2531191-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012072782-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012016980-A2 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011095584-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | disclosed |